OncoSec Medical Inc (ONCSQ)

[$Moneypenny$]

One more thing about the potential combination mouse study:

Do you think its possible that Dr. Heller might be presenting the results of a combination mouse trial at the ASGCT? It might make sense for the following reasons:

1. Dr. Heller is presenting at ASGCT and he is in charge of the Old Dominion research project that has conducted the mouse studies.

2. The topic, which is quoted below, is specifically focused on results from Phase I and II Clinical Trials to "provide the rationale for an expanded study."

3. The only expanded trial is a Phase 2B combination trial involving anti-PD-1.

I'd love all you guys' thoughts on this. This might be another place for data to be released that could show immense possibilities for the combination study.

Richard Heller, PhD
Non-Viral Gene Transfer of pIL-12 for the Treatment of Melanoma: Results from Phase I and II Clinical Trials
Electrotransfer of plasmids encoding cytokines directly to tumors has been shown to generate a local and systemic anti-tumor effect in both preclinical and clinical studies. In the clinical studies, patients with in-transit cutaneous melanoma received at least one treatment cycle (days 1, 5, 8) of intratumor pIL-12 delivered by electrotransfer in up to four lesions per cycle. In both the Phase I and II trials increases in IL-12 levels and enhanced immune activity were observed and the therapy was well tolerated. Intratumor treatment with pIL-12 electro transfer exhibited a systemic antitumor immune response with activity in both treated and non-treated sites of disease and objective response to treatment. These positive results provide the rationale for an expanded study.